trending Market Intelligence /marketintelligence/en/news-insights/trending/kH90Qal2OK0NvtXbWLvEuQ2 content esgSubNav
In This List

Report: Takeda in talks with PE buyers for assets in Middle East, Africa, Russia

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: Takeda in talks with PE buyers for assets in Middle East, Africa, Russia

Takeda Pharmaceutical Co. Ltd. is in negotiations for a sale of its assets in Russia to Stada Arzneimittel Aktiengesellschaft and for divesting its assets in the Middle East and Africa to Acino International AG, Bloomberg News reported Oct. 10, citing anonymous sources.

Germany-based pharmaceuticals company Stada, which is owned by asset management firms Cinven Ltd. and Bain Capital LP, is in discussions with the Japanese company for its over-the-counter and prescription-drug assets in Russia, the news outlet noted.

Takeda is also close to finalizing a deal with private Swiss pharmaceutical company Acino International, which is owned by private equity companies Nordic Capital and Avista Capital Partners LP, for its assets in the Middle East and Africa.

Representatives for Takeda, Stada, Cinven, Bain, Nordic Capital and Avista declined to comment, according to Bloomberg News.

Takeda is also looking for buyers to sell its portfolio of over-the-counter and prescription drugs in emerging markets and western Europe in separate transactions, Bloomberg News reported in September.

The Japanese drugmaker said in 2018 that it plans to sell about $10 billion in assets to reduce debt and simplify its portfolio after acquiring Shire PLC for £46 billion.